Neoproct Yhdistelmäpakkaus (Fluocortolone Pivalate, Anhydrous Lidocaine Hydrochloride)

Fluocortolone pivalate, the active ingredient in Neoproct Yhdistelmäpakkaus, is a corticosteroid presented as a rectal formulation for local use. Combined with lidocaine hydrochloride, it is intended to reduce inflammation and relieve pain in conditions such as proctitis, hemorrhoids and anal fissures.

GNH USA supplies Neoproct Yhdistelmäpakkaus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neoproct Yhdistelmäpakkaus is used to manage inflammatory and painful conditions of the rectal area.

Rectal inflammation (proctitis): reduces swelling and promotes healing. Hemorrhoids: alleviates swelling and discomfort. Anal fissures: decreases inflammation and eases pain during bowel movements. General rectal pain and discomfort: provides local anaesthesia and anti‑inflammatory effect.

Local rectal administration of Neoproct Yhdistelmäpakkaus may be associated with a range of adverse reactions.

Common Side Effects: - Mild burning or stinging at the application site - Transient itching - Minor rectal irritation - Temporary increase in bowel movements - Mild headache

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Rectal ulceration or tissue necrosis - Systemic corticosteroid effects such as adrenal suppression - Persistent numbness or loss of sensation - Infection at the application site

Before using Neoproct Yhdistelmäpakkaus, consider the following precautions to ensure safe and effective therapy.

Pregnancy: consult a healthcare professional before use, as safety data are limited. Breastfeeding: discuss potential risks with a physician. Existing infections: avoid use on infected or ulcerated tissue. Concurrent corticosteroid therapy: monitor for additive systemic effects. Allergy to lidocaine or corticosteroids: contraindicated. Store below 25°C: keep in the original pack, protect from moisture and heat.

Neoproct Yhdistelmäpakkaus can interact with other medicines; the following interactions are recognised.

Major Interactions (Avoid): - Systemic corticosteroids: may increase risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise local corticosteroid levels. - Other local anesthetics: may cause cumulative nerve toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): corticosteroid may enhance bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined irritation of rectal mucosa. - Immunosuppressants: may reduce local immune response.